Doç. Dr. Murat Ayhan

Hekimin kurum profilinde kendi belirttiği tıbbi ilgi alanları. Kaynak: livhospital.com.

Deneyim

• DeneyimLiv Hospital Uluslivhospital.com
• DeneyimAdıyaman Üniversitesi Eğitim ve Araştırma Hastanesilivhospital.com
• Deneyimİstanbul Ümraniye Eğitim ve Araştırma Hastanesilivhospital.com

Eğitim

• 2001Kızıltepe Anadolu Lisesilivhospital.com
• 2007Dicle Üniversitesi Tıp Fakültesilivhospital.com
• 2014İstanbul Medeniyet Üniversitesi Göztepe Eğitim ve Araştırma Hastanesilivhospital.com
• 2021Kartal Şehir Hastanesilivhospital.com
• 2023Tıbbi Onkoloji Doçentilivhospital.com

• UzmanlıkTıbbi Onkolojilivhospital.comKaynaktan
• KurumLiv Hospital Vadistanbullivhospital.comKaynaktan
• Yayınlar36 yayınlivhospital.com profil sayfasıKaynaktan
• Son eşitleme04.11.2026 20:55https://www.livhospital.com/doc-dr-murat-ayhanlivhospital.com

1. Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.

   Kaynak: livhospital.com profil sayfası

2. Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.

   Kaynak: livhospital.com profil sayfası

3. Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.

   Kaynak: livhospital.com profil sayfası

4. Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.

   Kaynak: livhospital.com profil sayfası

5. Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.

   Kaynak: livhospital.com profil sayfası

6. Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.

   Kaynak: livhospital.com profil sayfası

7. Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.

   Kaynak: livhospital.com profil sayfası

8. Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.

   Kaynak: livhospital.com profil sayfası

9. Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.

   Kaynak: livhospital.com profil sayfası

10. Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.

    Kaynak: livhospital.com profil sayfası

26 yayın daha var; tamamı yakında.